Department of Biotechnology, Indian Institute of Technology Madras, Tamil Nadu, 600036, India.
CSIR-Central Drug Research Institute, Lucknow, 226014, India.
Chem Biol Interact. 2020 Dec 1;332:109298. doi: 10.1016/j.cbi.2020.109298. Epub 2020 Oct 27.
The on-going pandemic of COVID-19 wreaked by a viral infection of SARS-CoV-2, has generated a catastrophic plight across the globe. Interestingly, one of the hallmarks of COVID-19 is the so-called 'cytokine storm' due to attack of SARS-Cov-2 in the lungs. Considering, mesenchymal stem cells (MSCs) therapy could contribute against SARS-CoV-2 viruses attack because of their immune modulatory and anti-inflammatory ability linked to their stemness, to the arsenal of treatments for COVID-19. Another novel therapeutic strategies include the blockade of rampant generation of pro-inflammatory mediators like acute respiratory distress syndrome (ARDS), degradation of viral protein capsids by PROTACs, composed of Ubiquitin-proteasome framework, and ubiquitination-independent pathway directing the SARS-CoV-2 nucleocapsid protein (nCoV N) and proteasome activator (PA28γ), etc. This review is consequently an endeavour to highlight the several aspects of COVID-19 with incorporation of important treatment strategies discovered to date and putting the real effort on the future directions to put them into the perspective.
由 SARS-CoV-2 病毒感染引起的持续的 COVID-19 大流行,在全球范围内造成了灾难性的困境。有趣的是,COVID-19 的标志之一是所谓的“细胞因子风暴”,这是由于 SARS-Cov-2 在肺部的攻击。鉴于间充质干细胞(MSCs)疗法由于其与干性相关的免疫调节和抗炎能力,可能有助于对抗 SARS-CoV-2 病毒的攻击,因此它被纳入 COVID-19 的治疗方法中。另一种新的治疗策略包括阻断急性呼吸窘迫综合征(ARDS)等促炎介质的狂潮产生、由泛素-蛋白酶体框架组成的 PROTACs 降解病毒蛋白衣壳、以及通过非依赖泛素化途径靶向 SARS-CoV-2 核衣壳蛋白(nCoV N)和蛋白酶体激活剂(PA28γ)等。因此,本综述旨在强调 COVID-19 的几个方面,包括迄今为止发现的重要治疗策略,并为未来的方向做出实际努力,从整体上看待这些策略。